Synapto Ventures

We help technical founders solve their hardest operational and commercialization challenges - all with an eye towards building durable, generational companies. We invest $500K-1M and frequently lead or co-lead. We invest from incorporation to seed stage, with more than 80% of our investments at pre-seed or earlier. Investing in two areas: biological platforms and applied robotics. Biological platforms encompass everything from material science to synthetic biology to AI for drug discovery. Applied robotics includes autonomy, chemical automation, swarm robotics systems, and biomanufacturing, among many others. Our North Star We believe there is a better way. Scientific and technological innovation drive our civilization forward, but the impact of these innovations is muted if they aren’t translated into real world projects. Too many times we’ve seen real scientific breakthroughs curtailed - or their impact delayed - not because of lack of rigor or founder ability, but because the infrastructure and tools don’t exist to commercialize these innovations in a repeatable manner. While scientific founders are sometimes able to raise early capital based on their technology or their backgrounds, the path between that initial funding and their first institutional round is maddeningly unclear and often treacherous. The entrepreneurs who do make it through that gauntlet often need to raise multiple rounds of dilutive capital to get there - stumbling in the dark until they understand what milestones they need to unlock that subsequent financing and build a successful business. Our North Star is helping entrepreneurs commercialize their breakthrough to build durable, impactful, and ultimately generational companies. Our team has founded, invested, and advised deep tech companies for over a decade. We’ve experienced the recessions, the hype cycles, the breakthroughs, and the breakouts. We’ve seen all of the many ways that deep tech companies can fail, but we’ve also seen founders beat the odds and build historic companies, legacies, and movements. It is our greatest privilege to partner with these entrepreneurs.

The mission of the group is to identify early-stage companies with disruptive technologies that solve unmet needs in biologic drug R&D and production, as well as challenges in the diagnostics market. Investment selection is completed thorough a rigorous review process, which starts with in-depth market work, followed by due diligence according to Danaher’s best-in-class standard work.

We invest in early-stage opportunities that complement Takeda’s pipeline and products. Our mission is to create strategic growth opportunities for Takeda by investing and nurturing Innovative Life Science Companies in areas aligned with Takeda’s R&D focuses which include; Oncology, Gastroenterology, Neuroscience, and Rare Disease. Our aim is to access and support therapeutic and platform innovation working closely with academic innovators, entrepreneurs and investors. We invest in seeds or syndicated venture investing providing to the companies access to the resources of a multinational pharmaceutical company.

Cambrian Biopharma, a multi-asset longevity biotech, is building the medicines that will redefine healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. By partnering with leading academic institutions and biotech entrepreneurs all over the world, we are advancing a diversified pipeline of novel therapeutics, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve overall quality of life as we age. Cambrian is a Distributed Development Company (or DisCo) which combines the advantages of a venture capital firm and a big pharmaceutical company, with the nimbleness of a biotech startup. Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization. To date, we have 14 novel therapeutics in development, and having closed a Series C financing round in October 2021 which raised $100 million, we plan to expand the number of programs. Further, we expect to initiate clinical trials for three programs in the next 18 months.

We invest in the innovators behind the miracles of science who are passionate about improving human health. Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire. Our Approach As the corporate venture capital arm of Sanofi, we invest in top-tier biotech and digital health companies that focus on helping patients and transforming the practice of medicine. We invest across all stages of the private company lifecycle, from Seed to Series B and beyond, while leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value through future financings and IPO. How We Work Think of us like institutional venture capitalists with an added bonus: in addition to our investment, we aim to offer our portfolio companies select access to Sanofi’s expertise and capabilities in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization. Our goal is to foster strong relationships over time so when our portfolio company is ready to consider a partnership or acquisition, our colleagues on the BD and M&A teams can be a first and last call. We move quickly, we don’t believe in drawn-out processes, and we always aim to provide thoughtful feedback. Our Investment Focus We invest in early-stage biotech and digital health companies of strategic interest to Sanofi. We seek to accelerate all strategic focus while reaching into novel and emerging areas of science and technology. Here are some of the areas that we currently are thinking about: Rare diseases Immunology and inflammation Oncology Cell and gene therapy Vaccines Digital health and data science We can't do it alone - we would love to hear how we can team up to improve human health for people everywhere!

Bioqube Ventures is a specialist life sciences investment firm based in Europe and US with a global footprint. We source, finance and develop innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors. Bioqube Ventures is dedicated to funding therapeutic innovations: … a life sciences venture capital fund – dedicated to advancing exciting science in European and US ecosystems to breakthrough therapies for patients. … a fit-for-purpose dual investment model – besides more classical investments in investment rounds, we have special attention for venture creation projects that require additional experiments prior to creating new ventures. With our in-house factory model we are able to translate exciting science into trailblazing companies. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths. We believe in putting our expertise at work where it matters.